Cytokinetics (NASDAQ: CYTK) reported Q1 EPS of ($0.23), $0.11 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $10.1 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.